Tricept Life Sciences Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
as on 17-12-2024
- Paid Up Capital ₹ 5.00 M
as on 17-12-2024
- Company Age 5 Year, 6 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 7.00 M
as on 17-12-2024
- Satisfied Charges ₹ 5.00 M
as on 17-12-2024
- Revenue -0.63%
(FY 2022)
- Profit 101.73%
(FY 2022)
- Ebitda 182.39%
(FY 2022)
- Net Worth 2.34%
(FY 2022)
- Total Assets -7.08%
(FY 2022)
About Tricept Life Sciences
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 5.00 M.
The company currently has active open charges totaling ₹7.00 M. The company has closed loans amounting to ₹5.00 M, as per Ministry of Corporate Affairs (MCA) records.
Pendiyalam Dutt and Kamal Chand serve as directors at the Company.
- CIN/LLPIN
U24230TN2019PTC129881
- Company No.
129881
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
13 Jun 2019
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Company Details
- Location
Chennai, Tamil Nadu, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Tricept Life Sciences?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Pendiyalam Dutt  | Director | 13-Jun-2019 | Current |
| Kamal Chand | Director | 14-Mar-2022 | Current |
Financial Performance of Tricept Life Sciences.
Tricept Life Sciences Private Limited, for the financial year ended 2022, experienced Minor drop in revenue, with a 0.63% decrease. The company also saw a substantial improvement in profitability, with a 101.73% increase in profit. The company's net worth moved up by a moderate rise of 2.34%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Tricept Life Sciences?
In 2022, Tricept Life Sciences had a public holding of 25.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 18 May 2023 | ₹7.00 M | Open |
Others Creation Date: 21 Nov 2020 | ₹5.00 M | Satisfied |
How Many Employees Work at Tricept Life Sciences?
Tricept Life Sciences has a workforce of 43 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Tricept Life Sciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Tricept Life Sciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
